No Data
No Data
Top Research Reports for AstraZeneca, Accenture & AT&T
Hutchmed, AstraZeneca's Lung Cancer Combo Shrinks Tumors in Mid-stage Study
AstraZeneca Hits 4-week High
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year
AstraZeneca's Lung Cancer Drug Enhertu Gets Conditional Approval in China
Daiichi Sankyo/astrazeneca (AZN.US)'s 'Tecentriq' has been approved in China.
On October 14th, the official website of the China National Medical Products Administration disclosed that the new indication for lung cancer of the injection-type trastuzumab deruxtecan (Enhertu) declared by Daiichi Sankyo has obtained marketing approval. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate jointly developed by Astrazeneca (AZN.US) and Daiichi Sankyo.
No Data
No Data